These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 23692811)

  • 1. Radiological heterogeneity in response to chemotherapy is associated with poor survival in patients with colorectal liver metastases.
    van Kessel CS; Samim M; Koopman M; van den Bosch MA; Borel Rinkes IH; Punt CJ; van Hillegersberg R
    Eur J Cancer; 2013 Jul; 49(11):2486-93. PubMed ID: 23692811
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Liver metastases from colorectal cancer treated with conventional and antiangiogenetic chemotherapy: evaluation with liver computed tomography perfusion and magnetic resonance diffusion-weighted imaging.
    Anzidei M; Napoli A; Zaccagna F; Cartocci G; Saba L; Menichini G; Cavallo Marincola B; Marotta E; Di Mare L; Catalano C; Passariello R
    J Comput Assist Tomogr; 2011; 35(6):690-6. PubMed ID: 22082538
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evidence of intermetastatic heterogeneity for pathological response and genetic mutations within colorectal liver metastases following preoperative chemotherapy.
    Sebagh M; Allard MA; Bosselut N; Dao M; Vibert E; Lewin M; Lemoine A; Cherqui D; Adam R; Sa Cunha A
    Oncotarget; 2016 Apr; 7(16):21591-600. PubMed ID: 26943031
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical Significance of Discordance between Carcinoembryonic Antigen Levels and RECIST in Metastatic Colorectal Cancer.
    Kim IH; Lee JE; Yang JH; Jeong JW; Ro S; Oh ST; Kim JG; Choi MH; Lee MA
    Cancer Res Treat; 2018 Jan; 50(1):283-292. PubMed ID: 28494536
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Response to neoadjuvant chemotherapy does not predict overall survival for patients with synchronous colorectal hepatic metastases.
    Gallagher DJ; Zheng J; Capanu M; Haviland D; Paty P; Dematteo RP; D'Angelica M; Fong Y; Jarnagin WR; Allen PJ; Kemeny N
    Ann Surg Oncol; 2009 Jul; 16(7):1844-51. PubMed ID: 19224284
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Perioperative chemotherapy with or without bevacizumab in patients with metastatic colorectal cancer undergoing liver resection.
    Constantinidou A; Cunningham D; Shurmahi F; Asghar U; Barbachano Y; Khan A; Mudan S; Rao S; Chau I
    Clin Colorectal Cancer; 2013 Mar; 12(1):15-22. PubMed ID: 23021126
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association between imaging response and survival following neoadjuvant chemotherapy in patients with resectable colorectal liver metastases: A cohort study.
    Behrenbruch C; Prabhakaran S; Udayasiri D D; Michael M; Hollande F; Hayes I; Heriot AG; Knowles B; Thomson BN
    J Surg Oncol; 2021 Apr; 123(5):1263-1273. PubMed ID: 33524184
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Prognostic Significance of Metabolic Response Heterogeneity in Metastatic Colorectal Cancer.
    Hendlisz A; Deleporte A; Delaunoit T; Maréchal R; Peeters M; Holbrechts S; Van den Eynde M; Houbiers G; Filleul B; Van Laethem JL; Ceyssens S; Barbuto AM; Lhommel R; Demolin G; Garcia C; El Mansy H; Ameye L; Moreau M; Guiot T; Paesmans M; Piccart M; Flamen P
    PLoS One; 2015; 10(9):e0138341. PubMed ID: 26421426
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Response evaluation in patients with colorectal liver metastases: RECIST version 1.1 versus modified CT criteria.
    Chung WS; Park MS; Shin SJ; Baek SE; Kim YE; Choi JY; Kim MJ
    AJR Am J Roentgenol; 2012 Oct; 199(4):809-15. PubMed ID: 22997372
    [TBL] [Abstract][Full Text] [Related]  

  • 10. What is the Prognostic Value of a Discordant Radiologic and Pathologic Response in Patients Undergoing Resection of Colorectal Liver Metastases After Preoperative Chemotherapy?
    Brouquet A; Blot C; Allard MA; Lazure T; Sebbagh M; Gayet M; Lewin M; Adam R; Penna C; Sa Cunha A; Benoist S
    Ann Surg Oncol; 2020 Aug; 27(8):2877-2885. PubMed ID: 32144619
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Downstaging by regional chemotherapy of non-resectable isolated colorectal liver metastases.
    Link KH; Pillasch J; Formentini A; Sunelaitis E; Leder G; Safi F; Kornmann M; Beger HG
    Eur J Surg Oncol; 1999 Aug; 25(4):381-8. PubMed ID: 10419708
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of timing and cycles of systemic chemotherapy on survival outcome of colorectal liver metastases patients treated by percutaneous microwave ablation.
    Zhang K; Yu J; Zhou F; Yu X; Li X; Wang J; Han Z; Cheng Z; Liang P
    Int J Hyperthermia; 2016 Aug; 32(5):531-8. PubMed ID: 27121037
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Adjuvant systemic chemotherapy with or without bevacizumab in patients with resected liver metastases from colorectal cancer.
    Turan N; Benekli M; Koca D; Ustaalioglu BO; Dane F; Ozdemir N; Ulas A; Oztop I; Gumus M; Ozturk MA; Berk V; Kucukoner M; Uner A; Balakan O; Helvaci K; Ozkan S; Yilmaz U; Buyukberber S;
    Oncology; 2013; 84(1):14-21. PubMed ID: 23076023
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Changes in CT morphology can be an independent response marker for patients receiving regorafenib for colorectal liver metastases: retrospective pilot study.
    Ozaki Y; Shindoh J; Gonoi W; Nishioka Y; Kondoh C; Tanabe Y; Matoba S; Kuroyanagi H; Hashimoto M; Takano T
    BMC Cancer; 2018 Feb; 18(1):138. PubMed ID: 29402244
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of baseline sum of longest diameter in target lesions by RECIST on survival of patients with metastatic colorectal cancer.
    Machida N; Yoshino T; Boku N; Hironaka S; Onozawa Y; Fukutomi A; Yamazaki K; Yasui H; Taku K; Asaka M
    Jpn J Clin Oncol; 2008 Oct; 38(10):689-94. PubMed ID: 18845522
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Is Liver Transplantation an Option in Colorectal Cancer Patients with Nonresectable Liver Metastases and Progression on All Lines of Standard Chemotherapy?
    Dueland S; Hagness M; Line PD; Guren TK; Tveit KM; Foss A
    Ann Surg Oncol; 2015 Jul; 22(7):2195-200. PubMed ID: 25297902
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Morphological response and tumor shrinkage as predictive factors in metastatic colorectal cancer treated with first-line capecitabine, oxaliplatin, and bevacizumab.
    Nagaoka T; Osumi H; Ueno T; Ooki A; Wakatsuki T; Nakayama I; Ogura M; Takahari D; Chin K; Matsueda K; Yamaguchi K; Shinozaki E
    Int J Clin Oncol; 2023 Sep; 28(9):1191-1199. PubMed ID: 37349660
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Is complete liver resection without resection of synchronous lung metastases justified?
    Mise Y; Kopetz S; Mehran RJ; Aloia TA; Conrad C; Brudvik KW; Taggart MW; Vauthey JN
    Ann Surg Oncol; 2015 May; 22(5):1585-92. PubMed ID: 25373535
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic factors and survival after resection of colorectal liver metastasis in the era of preoperative chemotherapy: an 11-year single-centre study.
    John SK; Robinson SM; Rehman S; Harrison B; Vallance A; French JJ; Jaques BC; Charnley RM; Manas DM; White SA
    Dig Surg; 2013; 30(4-6):293-301. PubMed ID: 23969407
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Selective intra-arterial chemotherapy with floxuridine as second- or third-line approach in patients with unresectable colorectal liver metastases.
    Samaras P; Breitenstein S; Haile SR; Stenner-Liewen F; Heinrich S; Feilchenfeldt J; Renner C; Knuth A; Pestalozzi BC; Clavien PA
    Ann Surg Oncol; 2011 Jul; 18(7):1924-31. PubMed ID: 21207165
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.